AlloVir, Inc. (ALVR) gets the FDA clearance.

AlloVir, Inc. announces the FDA clearance on investigation of new drug ALVR109 for the treatment of COVID-19. It is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients. Proof-of-concept clinical trial with ALVR109 is planed to begin in the fourth quarter of 2020.